Pioneering enabling technologies to decode the epiProteome

Our lab is at the forefront of epiProteome research, leveraging an interdisciplinary approach that integrates biochemistry, cell biology, proteomics, and computational tools to develop cutting-edge technologies. We have pioneered three transformative platform technologies that allow us to systematically dissect the regulatory landscape of protein modifications and degradation dynamics in cancer and immune-related diseases:

PTM Profiling

A high-throughput platform for mapping post-translational modification (PTM) activity directly from biological specimens. This approach enables the identification of PTM signatures associated with distinct clinical conditions, providing a functional readout of disease states beyond genomic and transcriptomic analyses (Cell, Merbl et al., 2013).

PROMISE (Protein Modification Integrated Search Engine)

A computational framework designed to uncover modification states across the proteome, illuminating previously uncharted regions of the "dark proteome." This powerful tool facilitates large-scale, unbiased PTM discovery, enhancing our ability to decode complex regulatory mechanisms driving oncogenic and immune signaling (Nature Biotech, Kacen et al., 2023).

Proteasomal Profiling

A novel mass spectrometry-based technology that enables single-peptide resolution analysis of proteasome heterogeneity and the degradation landscape. By capturing the specificity of proteasomal cleavage events, this platform provides critical insights into protein turnover, antigen presentation, and the dynamic regulation of oncogenic pathways (Nature Biotech, Levy et al., 2018).

By continuously developing and refining these pioneering technologies, our lab is uncovering new dimensions of proteomic regulation, revealing novel biomarkers, and identifying therapeutic vulnerabilities that can be leveraged across different human diseases.